8-K: Microbot Medical Announces Acceptance of Late-Breaking Abstract at Society of Interventional Radiology Annual Meeting

Microbot Medical's ACCESS-PVI trial data on the LIBERTY Endovascular Robotic System will be presented at the Society of Interventional Radiology (SIR) annual meeting.

Summary

• Microbot Medical Inc. announced the acceptance of a late-breaking abstract for presentation at the Society of Interventional Radiology (SIR) annual meeting.
• The meeting will be held in Nashville, TN, from March 29 to April 2, 2025.
• The presentation will feature data from the ACCESS-PVI trial, which evaluated the performance and safety of the LIBERTY Endovascular Robotic System in patients undergoing peripheral vascular interventions.
• The presentation is scheduled for Wednesday, April 2, 2025, from 11:33 AM to 11:42 AM CT.
• The presenter will be Francois Cornelis, MD, PhD, FCIRSE, from Memorial Sloan Kettering Cancer Center.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the acceptance of the abstract and the opportunity to present at a major conference. However, the company's pre-commercial stage and the inherent risks in the medical device industry temper the enthusiasm.

Positives

• Acceptance of the late-breaking abstract indicates high interest from the SIR scientific committee in endovascular robotics.
• The presentation offers an opportunity to showcase the potential benefits of the LIBERTY system to potential users.
• The ACCESS-PVI trial data provides evidence of the performance and safety of the LIBERTY system.

Risks

• The company's future financial and operating results are subject to risks and uncertainties.
• The company needs and must obtain additional working capital to continue its transition to a commercially focused company.
• Development and commercialization of the LIBERTY Endovascular Robotic System involves inherent risks.
• Regulatory pathways and approvals, including FDA 510(k) clearance, are uncertain.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries may impact the company.
• Maintenance of intellectual property rights is crucial.

Future Outlook

The company's future growth depends on research, technology, clinical development, commercialization, and potential opportunities for Microbot Medical Inc. and its subsidiaries. These are forward-looking statements that involve risks and uncertainties.

Management Comments

• Harel Gadot, Chairman, CEO and President, commented that the acceptance of the late-breaking news is critically important and allows the Principal Investigators (PI) to present the data for the first time at the SIR annual meeting, especially since the primary attendees at this conference are potential users of LIBERTY.
• Harel Gadot believes that the potential benefits of LIBERTY will be meaningful and significant to the audience.

Industry Context

This announcement highlights the growing interest in endovascular robotics within the interventional radiology field. The presentation of the ACCESS-PVI trial data at a major conference like SIR suggests that Microbot Medical is seeking to establish its LIBERTY system as a key technology in this space.

Comparison to Industry Standards

• It's difficult to compare Microbot Medical directly to industry standards without specific financial data or performance metrics from the ACCESS-PVI trial.
• However, companies like Intuitive Surgical (ISRG) with the da Vinci Surgical System set a high bar for robotic surgery in terms of clinical adoption and market penetration.
• Other companies in the endovascular space, such as Siemens Healthineers and Philips, offer imaging and navigation technologies that could be considered competitive or complementary to Microbot's robotic system.
• The success of LIBERTY will depend on its ability to demonstrate superior clinical outcomes, ease of use, and cost-effectiveness compared to existing technologies.

Stakeholder Impact

• Positive for shareholders as it signals progress in the development and potential commercialization of the LIBERTY system.
• Potential benefits for patients through improved quality of care and access to advanced robotic systems.
• Potential benefits for providers through the elimination of traditional barriers to accessing advanced robotic systems.

Next Steps

• Presentation of the ACCESS-PVI trial data at the SIR annual meeting from March 29 to April 2, 2025.
• Continued development and commercialization efforts for the LIBERTY Endovascular Robotic System.
• Pursuit of regulatory approvals, including FDA 510(k) clearance.

Key Dates

Keywords

LIBERTY Endovascular Robotic System, Society of Interventional Radiology, ACCESS-PVI trial, Microbot Medical, Endovascular robotics, Medical device